Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Last Friday we noted that a new paper by Vickers et al. has formally recommended that PSA velocity be removed from guidelines on the use of diagnostic data to decide whether a man should have a biopsy to assess his potential risk for prostate cancer. We expressed no opinion on the article at that time
Filed under: Diagnosis, Risk | Tagged: best practice, biopsy, guideline, PSA, velocity | 2 Comments »
Every two years, the Prostate Cancer Research Program of the Department of Defense’s Congressionally Directed Medical Research Program holds the “Innovative Minds in Prostate Cancer Today” or IMPaCT meeting. The next such meeting will be held on March 9 to 12 this year in Orlando, Florida.
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Prevention, Risk, Treatment | Tagged: IMPACT, PCRP, Prostate Cancer Research Program, research | 1 Comment »
A new report from the Cleveland Clinic provides us with rigorous data on the acceptability and outcomes of active surveillance (AS) as a management strategy for men diagnosed with low-risk prostate cancer — regardless of their age at the time of diagnosis.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: acceptance, active surveillance, age, outcome | 1 Comment »
A new report in the Journal of the National Cancer Institute states that since the publication of the PLCO and ERSCP data on prostate cancer screening in early 2009, there has been a small reduction in the number of men requesting PSA testing at eight group practices in the Veterans Health Administration Pacific Northwest Network.
Filed under: Diagnosis, Risk | Tagged: decrease, screening, VA | Leave a Comment »
A new analysis of data from > 5,500 men who participated in the Prostate Cancer Prevention Trial has directly challenged the recommendation in some clinical guidelines regarding the use of PSA velocity as an indicator for immediate biopsy.
Filed under: Diagnosis, Risk | Tagged: biopsy, guidelines, PSA, velocity | Leave a Comment »
If you are a Medicare patient, where you live may have a profound effect on how you get treated for localized prostate cancer (among other things), according to a new report from The Dartmouth Institute for Health Policy and Clinical Practice.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: city, decision-making, region, surgery | Leave a Comment »
There’s an interesting interview with Dr. Anthony Zeitman — the president of the American Society of Radiation Oncology (ASTRO) — in the most recent issue of The ASCO Post — a news magazine distributed to members of ASCO.
Filed under: Diagnosis, Management, Treatment, Uncategorized | Tagged: Management, practice, reality, technology | 2 Comments »
Men are often torn between involving their family members in health-care decision-making and trying to keep the whole issue to themselves because they just “don’t want to make a big deal about it.” But prostate cancer is a big deal — for the patient and for his immediate family.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: decision-making, encourage, partner, provider | Leave a Comment »
Since the widespread adoption of the PSA test in the early to mid-1990s, there has been a gradual but constant tendency for a higher proportion of prostate cancer patients to be diagnosed with earlier stages of disease (i.e., much more clinical stage T1cNoM0 and much less TxNxM1). This process is known as “stage migration.”
Filed under: Management, Treatment | Tagged: radical prostatectomy, reverse, stage migration | Leave a Comment »
Prior studies have looked at the question of patient regret after election of specific types of treatment for localized prostate cancer. Unsurprisingly, this effect is not confined to patients in the USA, and a new study from Taiwan indicates that patient regret may be as high as 31 percent after radical prostatectomy (RP).
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: outcome, radical prostatectomy, regret, risk, side effects | Leave a Comment »
To date there have been few data from well-documented, prospective series of patients receiving any form of focal therapy as treatment for localized prostate cancer, and the criteria for the appropriate clinical use of focal therapy are still a matter of considerable debate.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: focal therapy, hemiablative, HIFU, high-intensity focused ultrasound, outcome | 6 Comments »
There are two potentially good reasons for a patient who is receiving treatment with an LHRH agonist to switch from one product to another: the first is because he is having a problem with the adverse effects of his initial LHRH therapy; the second is because he has a rising PSA on the initial LHRH [...]
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: LHRH agonist, outcome, switch | 1 Comment »
This is hardly a radical new finding but yet another study has recently shown that we are over-using expensive scanning tests in the work-up of patients diagnosed with low- and intermediate-risk prostate cancer — and under-using these tests in men initially diagnosed with high-risk disease.
Filed under: Diagnosis, Management, Risk | Tagged: bone scan, CT scan, MRI, necessary, PET scan | 1 Comment »
Over the past year we have provided readers with extensive information about some of the new forms of therapy such as abiraterone acetate, MDV3100, TAK-700, and others that have shown great promise and are already in Phase III clinical trials for post-chemotherapy and chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC).
Filed under: Drugs in development | Tagged: castation-resistant, development, drugs, mCRPC | 5 Comments »
Over 200 posters and other presentations of new data, as well as many other discussions and lectures, were offered yesterday in the prostate cancer sessions at the Genitourinary Cancers Symposium in Orlando.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Treatment | Tagged: adjuvant, ADT, bicalutamide, CyberKnife, dutasteride, intermittent, pomegranate, SBRT, screening | 1 Comment »
Search for new and
ongoing trials on the
CTAG PCa web site